ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1579

Exploring the Pulmonary Vascular Changes on Computed Tomography in predicting progression and mortality of Systemic Sclerosis-associated Interstitial Lung Disease

Maria Iacovantuono1, Nicholas landini2, lisa Jungblut3, Florian Käs4, Rucsandra Dobrota5, Sinziana Muraru6, Carina Mihai7, Muriel Elhai8, Mike Becker9, Maria Sole Chimenti10, Thomas Frauenfelder3, Anna-Maria Hoffmann-Vold11, Oliver Distler12 and Cosimo Bruni13, 1Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University, Rome, Italy. Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Spinete, Italy, 2Department of Radiological Sciences, Oncology and Pathology, "Sapienza" University, Policlinico Umberto I, Rome, Italy. Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Rueil Malmaison, France, 3Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, zurich, Switzerland, 4Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, 5Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, 6University of Zurich, University Hospital Zurich, Zürich, Switzerland, 7University Hospital Zurich, University of Zurich, Zurich, Switzerland, 8Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, Schlieren, Switzerland, 9Dept. of Rheumatology, University Hospital Zurich, Zürich, Switzerland, 10Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University, Rome, Italy, Roma, Italy, 11Oslo University Hospital, Oslo, Norway, 12Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, 13Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland

Meeting: ACR Convergence 2025

Keywords: Imaging, interstitial lung disease, prognostic factors, risk factors, Scleroderma, Systemic

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1553–1591) Systemic Sclerosis & Related Disorders – Clinical Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Interstitial lung disease (ILD) is the main cause of mortality in systemic sclerosis (SSc). Among radiomics features, the automated quantification of pulmonary vascular volume (PVV) on high-resolution computed tomography (HRCT) was predictive of survival and functional changes in idiopathic pulmonary fibrosis (IPF) and rheumatoid arthritis (RA)-associated ILD (Jacob, 2018). In SSc, PVV was associated with ILD severity (extent on HRCT, pulmonary function tests values: pFVC%, pDLCO%). Here, we explored the predictive value of CT-derived radiomics features for mortality and ILD progression in SSc-ILD.

Methods: We included SSc patients from a single referral centre with ILD present on HRCT and at least one follow-up visit. The progression analysis focused on patients with lung function repeated within 12±3 months. ILD progression was defined as at least one of the following:FVC relative decline ≥ 10 %FVC relative decline ≥ 10 % or FVC 5-9% and DLCO relative decline ≥ 15%FVC absolute decline ≥ 5%FVC absolute decline ≥ 5 or DLCO absolute decline ≥ 10%HRCT scans underwent lung texture analysis (LTA, Imbio). The percentage distribution of ground-glass, reticular, honeycombing (the latter two defining “fibrotic alterations”), hyperlucency, normal lung and PVV was quantified in upper, middle and lower zones and the whole lung. Survival analysis was performed from the first ILD-positive CT until last contact (death or alive status), using Cox proportional hazards models, with radiomics parameters adjusted for the SCOpE score (Elhai, 2017). Radiomics predictors of ILD progression were assessed using the logistic Generalized Estimating Equations (GEE), adjusted for established risk factors.

Results: Among 267 SSc-ILD patients, 65 (24%) deaths were recorded over a median follow up of 42 (27-110) months. Patients who died were older, clinically and functionally more severely impaired (Table I) and with higher extent of PVV% and parenchymal alterations in all lung zones (Table II). In a multivariable Cox model, the PVV% of the upper zones (HR 1.28, 95% CI 1.12-1.47) and the SCOpE score (HR 1.22, 95% CI 1.15-1.28) independently predicted mortality (Fig IA).Among the 261 yearly follow-ups from 160 SSc-ILD patients, we recorded 99 episodes of ILD progression (38%), occurring in 64 patients (40%). Patients with progressive ILD had more frequently increased inflammatory markers, better-preserved pulmonary function tests (Table I), but comparable radiomics changes versus non-progressors (Table II). In a multivariable model integrating clinical and radiomics predictors selected through univariable analysis, only pDLCO% (OR 1.02, 95% CI 1.01-1.04) and pFVC% (OR 1.03, 95% CI 1.01-1.05) were independently associated with ILD progression (Fig IB). Comparable results were obtained when each progression definition was analysed separately.

Conclusion: In line withRA-ILD and IPF, PVV% of the upper zones significantly predicts mortality in SSc-ILD. Conversely, we could not detect radiomics predictors for ILD progression. Further studies are needed to support the identification of patients at risk of ILD progression and prompt therapeutic interventions.

Supporting image 1Table I. Clinical and functional characteristics of the study population.

ACA: anti-centromere antibodies; ATA: anti-topoisomerase I antibodies; ARA: anti-RNA polymerase III antibodies; antiPm-Scl: anti-PM-scleroderma-antibodies; dcSSc: diffuse cutaneous systemic sclerosis; NVC: nailfold videocapillaroscopy; NYHA: New York Hearth Association; pFVC%: predicted forced vital capacity; pDLCO/SB%: predicted diffusion of the lung for carbon monoxide on single breath; 6MWT: 6 minutes walking test

Increased inflammatory markers defined as ESR or/and CRP above normal levels

Supporting image 2Table II. Distribution of radiomics parameters in the total lungs among systemic sclerosis patients with progressive disease or death

Fibrotic alterations = reticular pattern + honeycombing

Supporting image 3Fig I. Forrest plot showing predictive radiomics and clinical risk factors for mortality (IA) and progression (IB).


Disclosures: M. Iacovantuono: Eli Lilly, 12, congress support, EULAR long-term research felloship, 5; N. landini: None; l. Jungblut: None; F. Käs: None; R. Dobrota: Actelion, 5, 6, Amgen, 6, Boehringer-Ingelheim, 6, Iten-Kohaut, 5, Otsuka, 6, Pfizer, 5, Walter und Gertrud Siegenthaler Fellowship, 5; S. Muraru: AstraZeneca, 12, congress support; C. Mihai: Boehringer Ingelheim, 2, 12, congress support, Janssen, 2, MED Talks Switzerland, 6, Medbase, 6, MedTrix, 6, Mepha, 6, Novartis, 6, PlayToKnow, 6; M. Elhai: AstraZeneca, 12, Congress support, Boehringer-Ingelheim, 6, FOREUM, 5, Iten Kohaut foundation, 5, Janssen, 12, Congress support, Kurt und Senta Herrmann foundation, 5, Novartis, 5, Pfizer, 5, University Zurich, 5; M. Becker: Foundation for research in Rheumatology (FOREUM), 5, GSK, 6, 12, congress support, Novartis Foundation for Medical-biological Research, 5, 6, Vifor, 6, 12, congress support; M. Chimenti: None; T. Frauenfelder: AstraZeneca, 2, Bayer, 6, Siemens, 6; A. Hoffmann-Vold: AbbVie, 2, Avalyn, 2, Boehringer Ingelheim, 2, 5, 6, 12, Medical writing support provided by Fleishman Hillard., Bristol-Myers Squibb, 2, Calluna Pharma, 2, Genentech, 2, Janssen, 2, 5, 6, Medscape, 2, 6, Merck Sharp & Dohme, 2, 6, Novartis, 6, Pliant Therapeutics, 2, Roche, 2, 6, Werfen, 2; O. Distler: 4P-Pharma, 2, 6, AbbVie/Abbott, 2, 6, Acceleron, 2, 6, Acepodia Biotech, 2, 6, Aera, 2, 6, AnaMar, 2, 6, Anaveon AG, 2, 6, Argenx, 2, 6, AstraZeneca, 2, 6, BMS, 2, 5, 6, Calluna (Arxx), 2, 6, Cantargia AB, 2, 6, CITUS AG, 8, CSL Behring, 2, 6, EMD Serono, 2, 6, Galapagos, 2, 6, Galderma, 2, 6, Gossamer, 2, 6, Hemetron, 2, 5, 6, Innovaderm, 2, 5, 6, Janssen, 2, 6, Mediar, 2, 5, 6, mir-29 for the treatment of systemic sclerosis, 10, Mitsubishi Tanabe, 2, 5, 6, MSD Merck, 2, 6, Nkarta Inc., 2, 6, Novartis, 2, 6, Orion, 2, 6, Pilan, 2, 6, Prometheus, 2, 6, Quell, 2, 6, Sumitomo, 2, 5, 6, Topadur, 2, 5, 6, UCB, 2, 5, 6; C. Bruni: Boehringer Ingelheim, 2, EMDO Foundation, 5, Iten-Kohaut Foundation, 5, Scleroderma Clinical Trials Consortium (SCTC), 5, Scleroderma Research Foundation (SRF), 2.

To cite this abstract in AMA style:

Iacovantuono M, landini N, Jungblut l, Käs F, Dobrota R, Muraru S, Mihai C, Elhai M, Becker M, Chimenti M, Frauenfelder T, Hoffmann-Vold A, Distler O, Bruni C. Exploring the Pulmonary Vascular Changes on Computed Tomography in predicting progression and mortality of Systemic Sclerosis-associated Interstitial Lung Disease [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/exploring-the-pulmonary-vascular-changes-on-computed-tomography-in-predicting-progression-and-mortality-of-systemic-sclerosis-associated-interstitial-lung-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/exploring-the-pulmonary-vascular-changes-on-computed-tomography-in-predicting-progression-and-mortality-of-systemic-sclerosis-associated-interstitial-lung-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology